![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | SLC29A4 | Human | (R)-adrenaline | increases uptake | EXP | | 6480464 | SLC29A4 protein results in increased uptake of Epinephrine | CTD | PMID:20858707 | SLC29A4 | Human | (R)-noradrenaline | increases uptake | EXP | | 6480464 | SLC29A4 protein results in increased uptake of Norepinephrine | CTD | PMID:20858707 | SLC29A4 | Human | 1,1'-diethyl-2,2'-cyanine | multiple interactions | EXP | | 6480464 | pseudoisocyanine inhibits the reaction [SLC29A4 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] | CTD | PMID:20858707 | SLC29A4 | Human | 1,2-dichloroethane | increases expression | ISO | Slc29a4 (Mus musculus) | 6480464 | ethylene dichloride results in increased expression of SLC29A4 mRNA | CTD | PMID:28189721 and PMID:28960355 | SLC29A4 | Human | 1,2-dimethylhydrazine | increases expression | ISO | Slc29a4 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in increased expression of SLC29A4 mRNA | CTD | PMID:22206623 | SLC29A4 | Human | 1-naphthyl isothiocyanate | decreases expression | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | 1-Naphthylisothiocyanate results in decreased expression of SLC29A4 mRNA | CTD | PMID:30723492 | SLC29A4 | Human | 17beta-estradiol | multiple interactions | EXP | | 6480464 | [Estradiol co-treated with TGFB1 protein] results in increased expression of SLC29A4 mRNA | CTD | PMID:30165855 | SLC29A4 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Slc29a4 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SLC29A4 mRNA | CTD | PMID:19465110 | SLC29A4 | Human | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of SLC29A4 mRNA | CTD | PMID:32109520 and PMID:33387578 | SLC29A4 | Human | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Slc29a4 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of SLC29A4 mRNA | CTD | PMID:28213091 | SLC29A4 | Human | 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine | increases response to substance | EXP | | 6480464 | SLC29A4 results in increased susceptibility to Puromycin Aminonucleoside | CTD | PMID:19357181 | SLC29A4 | Human | 6-propyl-2-thiouracil | decreases expression | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | Propylthiouracil results in decreased expression of SLC29A4 mRNA | CTD | PMID:30047161 | SLC29A4 | Human | acetamide | decreases expression | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | acetamide results in decreased expression of SLC29A4 mRNA | CTD | PMID:31881176 | SLC29A4 | Human | all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of SLC29A4 mRNA | CTD | PMID:33167477 | SLC29A4 | Human | aristolochic acid A | decreases expression | EXP | | 6480464 | aristolochic acid I results in decreased expression of SLC29A4 mRNA | CTD | PMID:33212167 | SLC29A4 | Human | atrazine | increases expression | EXP | | 6480464 | Atrazine results in increased expression of SLC29A4 mRNA | CTD | PMID:22378314 | SLC29A4 | Human | atrazine | decreases expression | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | Atrazine results in decreased expression of SLC29A4 mRNA | CTD | PMID:36841081 | SLC29A4 | Human | benzo[a]pyrene | decreases methylation | EXP | | 6480464 | Benzo(a)pyrene results in decreased methylation of SLC29A4 3' UTR | CTD | PMID:27901495 | SLC29A4 | Human | benzo[a]pyrene | affects methylation | EXP | | 6480464 | Benzo(a)pyrene affects the methylation of SLC29A4 5' UTR and Benzo(a)pyrene affects the methylation of SLC29A4 promoter | CTD | PMID:27901495 | SLC29A4 | Human | benzo[b]fluoranthene | increases expression | ISO | Slc29a4 (Mus musculus) | 6480464 | benzo(b)fluoranthene results in increased expression of SLC29A4 mRNA | CTD | PMID:26377693 | SLC29A4 | Human | bis(2-ethylhexyl) phthalate | decreases expression | EXP | | 6480464 | Diethylhexyl Phthalate results in decreased expression of SLC29A4 mRNA | CTD | PMID:31163220 | SLC29A4 | Human | bis(2-ethylhexyl) phthalate | multiple interactions | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC29A4 mRNA | CTD | PMID:31199487 | SLC29A4 | Human | bisphenol A | decreases methylation | ISO | Slc29a4 (Mus musculus) | 6480464 | bisphenol A results in decreased methylation of SLC29A4 promoter | CTD | PMID:27312807 | SLC29A4 | Human | bisphenol A | affects expression | EXP | | 6480464 | bisphenol A affects the expression of SLC29A4 mRNA | CTD | PMID:30903817 | SLC29A4 | Human | bisphenol A | increases expression | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | bisphenol A results in increased expression of SLC29A4 mRNA | CTD | PMID:30816183 more ... | SLC29A4 | Human | bromobenzene | decreases expression | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | bromobenzene results in decreased expression of SLC29A4 mRNA | CTD | PMID:32479839 | SLC29A4 | Human | butanal | decreases expression | EXP | | 6480464 | butyraldehyde results in decreased expression of SLC29A4 mRNA | CTD | PMID:26079696 | SLC29A4 | Human | Butylbenzyl phthalate | multiple interactions | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC29A4 mRNA | CTD | PMID:31199487 | SLC29A4 | Human | C60 fullerene | decreases expression | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | fullerene C60 results in decreased expression of SLC29A4 mRNA | CTD | PMID:19167457 | SLC29A4 | Human | chlorpyrifos | increases expression | ISO | Slc29a4 (Mus musculus) | 6480464 | Chlorpyrifos results in increased expression of SLC29A4 mRNA | CTD | PMID:37019170 | SLC29A4 | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in increased expression of SLC29A4 mRNA | CTD | PMID:27392435 | SLC29A4 | Human | cisplatin | increases expression | EXP | | 6480464 | Cisplatin results in increased expression of SLC29A4 mRNA | CTD | PMID:27392435 | SLC29A4 | Human | Cuprizon | increases expression | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | Cuprizone results in increased expression of SLC29A4 mRNA | CTD | PMID:26577399 and PMID:27523638 | SLC29A4 | Human | cyclosporin A | decreases expression | EXP | | 6480464 | Cyclosporine results in decreased expression of SLC29A4 mRNA | CTD | PMID:24907557 and PMID:25562108 | SLC29A4 | Human | cyclosporin A | decreases methylation | EXP | | 6480464 | Cyclosporine results in decreased methylation of SLC29A4 promoter | CTD | PMID:27989131 | SLC29A4 | Human | diazinon | increases methylation | EXP | | 6480464 | Diazinon results in increased methylation of SLC29A4 gene | CTD | PMID:22964155 | SLC29A4 | Human | dibenz[a,h]anthracene | increases expression | ISO | Slc29a4 (Mus musculus) | 6480464 | 1 more ... | CTD | PMID:26377693 | SLC29A4 | Human | dibutyl phthalate | increases expression | ISO | Slc29a4 (Mus musculus) | 6480464 | Dibutyl Phthalate results in increased expression of SLC29A4 mRNA | CTD | PMID:21266533 | SLC29A4 | Human | dibutyl phthalate | multiple interactions | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC29A4 mRNA | CTD | PMID:31199487 | SLC29A4 | Human | diethyl phthalate | multiple interactions | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC29A4 mRNA | CTD | PMID:31199487 | SLC29A4 | Human | diisobutyl phthalate | multiple interactions | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC29A4 mRNA | CTD | PMID:31199487 | SLC29A4 | Human | diisononyl phthalate | multiple interactions | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC29A4 mRNA | CTD | PMID:31199487 | SLC29A4 | Human | dimethylarsinic acid | multiple interactions | ISO | Slc29a4 (Mus musculus) | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC29A4 mRNA | CTD | PMID:34876320 | SLC29A4 | Human | dopamine | increases uptake | EXP | | 6480464 | SLC29A4 protein results in increased uptake of Dopamine | CTD | PMID:20858707 | SLC29A4 | Human | doxorubicin | increases abundance | EXP | | 6480464 | SLC29A4 protein results in increased abundance of Doxorubicin | CTD | PMID:37453608 | SLC29A4 | Human | doxorubicin | multiple interactions | EXP | | 6480464 | Metformin inhibits the reaction [SLC29A4 protein results in increased abundance of Doxorubicin] | CTD | PMID:37453608 | SLC29A4 | Human | FR900359 | increases phosphorylation | EXP | | 6480464 | FR900359 results in increased phosphorylation of SLC29A4 protein | CTD | PMID:37730182 | SLC29A4 | Human | furan | decreases expression | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | furan results in decreased expression of SLC29A4 mRNA | CTD | PMID:25539665 | SLC29A4 | Human | histamine | increases uptake | EXP | | 6480464 | SLC29A4 protein results in increased uptake of Histamine | CTD | PMID:20858707 | SLC29A4 | Human | metformin | multiple interactions | EXP | | 6480464 | Metformin inhibits the reaction [SLC29A4 protein results in increased abundance of Doxorubicin] | CTD | PMID:37453608 | SLC29A4 | Human | methimazole | decreases expression | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | Methimazole results in decreased expression of SLC29A4 mRNA | CTD | PMID:30047161 | SLC29A4 | Human | methylarsonic acid | multiple interactions | ISO | Slc29a4 (Mus musculus) | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC29A4 mRNA | CTD | PMID:34876320 | SLC29A4 | Human | N-methyl-4-phenylpyridinium | affects uptake | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | SLC29A4 protein affects the uptake of 1-Methyl-4-phenylpyridinium | CTD | PMID:21538354 | SLC29A4 | Human | N-methyl-4-phenylpyridinium | multiple interactions | EXP | | 6480464 | pseudoisocyanine inhibits the reaction [SLC29A4 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] | CTD | PMID:20858707 | SLC29A4 | Human | N-methyl-4-phenylpyridinium | increases uptake | EXP | | 6480464 | SLC29A4 protein results in increased uptake of 1-Methyl-4-phenylpyridinium | CTD | PMID:20858707 | SLC29A4 | Human | nickel sulfate | increases expression | EXP | | 6480464 | nickel sulfate results in increased expression of SLC29A4 mRNA | CTD | PMID:22714537 | SLC29A4 | Human | niclosamide | increases expression | EXP | | 6480464 | Niclosamide results in increased expression of SLC29A4 mRNA | CTD | PMID:36318118 | SLC29A4 | Human | paracetamol | affects expression | ISO | Slc29a4 (Mus musculus) | 6480464 | Acetaminophen affects the expression of SLC29A4 mRNA | CTD | PMID:17562736 | SLC29A4 | Human | paracetamol | increases expression | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | Acetaminophen results in increased expression of SLC29A4 mRNA | CTD | PMID:33387578 | SLC29A4 | Human | rifampicin | increases expression | EXP | | 6480464 | Rifampin results in increased expression of SLC29A4 mRNA | CTD | PMID:27199754 | SLC29A4 | Human | rotenone | increases expression | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | Rotenone results in increased expression of SLC29A4 mRNA | CTD | PMID:28374803 | SLC29A4 | Human | serotonin | increases uptake | EXP | | 6480464 | SLC29A4 protein results in increased uptake of Serotonin | CTD | PMID:20858707 | SLC29A4 | Human | silicon dioxide | decreases expression | EXP | | 6480464 | Silicon Dioxide analog results in decreased expression of SLC29A4 mRNA | CTD | PMID:25895662 | SLC29A4 | Human | sodium arsenate | multiple interactions | ISO | Slc29a4 (Mus musculus) | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC29A4 mRNA | CTD | PMID:34876320 | SLC29A4 | Human | sodium arsenite | multiple interactions | ISO | Slc29a4 (Mus musculus) | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC29A4 mRNA | CTD | PMID:34876320 | SLC29A4 | Human | T-2 toxin | decreases expression | ISO | Slc29a4 (Rattus norvegicus) | 6480464 | T-2 Toxin results in decreased expression of SLC29A4 mRNA | CTD | PMID:26141394 | SLC29A4 | Human | titanium dioxide | decreases methylation | ISO | Slc29a4 (Mus musculus) | 6480464 | titanium dioxide results in decreased methylation of SLC29A4 gene and titanium dioxide results in decreased methylation of SLC29A4 promoter | CTD | PMID:35295148 | SLC29A4 | Human | triptonide | increases expression | ISO | Slc29a4 (Mus musculus) | 6480464 | triptonide results in increased expression of SLC29A4 mRNA | CTD | PMID:33045310 | SLC29A4 | Human | tris(2-butoxyethyl) phosphate | affects expression | EXP | | 6480464 | tris(2-butoxyethyl) phosphate affects the expression of SLC29A4 mRNA | CTD | PMID:29024780 | SLC29A4 | Human | urethane | decreases expression | EXP | | 6480464 | Urethane results in decreased expression of SLC29A4 mRNA | CTD | PMID:28818685 | SLC29A4 | Human | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of SLC29A4 mRNA | CTD | PMID:25979313 | SLC29A4 | Human | valproic acid | increases methylation | EXP | | 6480464 | Valproic Acid results in increased methylation of SLC29A4 gene | CTD | PMID:29154799 | SLC29A4 | Human | zoledronic acid | decreases expression | EXP | | 6480464 | zoledronic acid results in decreased expression of SLC29A4 mRNA | CTD | PMID:24714768 | |